November 28
2021
download app
download appDOWNLOAD OUR APP
download google-play
download app-store
Dolores Utrilla
share
22nd September 2021
Consumer, Health & Environment Covid-19 Institutional law Internal Market

Commission signs contract for the supply of COVID-19 monoclonal antibody treatment

The European Commission has announced that it has signed a joint procurement framework contract with the pharmaceutical company Eli Lilly for the supply of a monoclonal antibody treatment for coronavirus patients, currently under rolling review by the European Medicines Agency (EMA).

The concerned medicine is a combination of two monoclonal antibodies (bamlanivimab and etesevimab) for the treatment of coronavirus patients who do not require oxygen but are at high risk of severe COVID-19. 18 Member States have signed up to the joint procurement for the purchase of up to 220,000 treatments, which will be possible once the medicine has received either a conditional marketing authorisation from EMA at EU level or an emergency use auth

×

Your privacy is important for us

We use cookies to improve the user experience. Please review privacy preferences.

Accept all Settings

Check our privacy policy and cookies policy.

Cookies